Going wide on immune system activation, with Jeffrey Meckler

Pharmaphorum Editor in Chief Jonah Comstock caught up again with Indaptus Therapeutics CEO Jeffrey Meckler after speaking with him last year at Reuters Pharma USA.

Meckler refreshes our memory about Indaptus’s unconventional approach to immunotherapy, based on activating a wide swath of the immune system at a low dose rather than focusing on one activator. And he gives an update on the company, which recently launched a Phase 2 in a combination trial with Tevimbra, the PD 1 inhibitor from BeOne, formerly known as BeiGene.

He talks about what the next steps for the company are, and the importance of trying new things and opening up the conversation about novel scientific approaches. And he shares his excitement about the meeting of the minds happening in the coming days at BIO 2025.